Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

Antonello Veccia, Orazio Caffo, Ugo De Giorgi, Giuseppe Di Lorenzo, Cinzia Ortega, Florinda Scognamiglio, Michele Aieta, Gaetano Facchini, Giovanni Mansueto, Rodolfo Mattioli, Giuseppe Procopio, Vittorina Zagonel, Alessandro D'Angelo, Gilbert Spizzo, Roberto Bortolus, Maddalena Donini, Giovanni Lo Re, Francesco Massari, Giovanni Vicario, Paolo A. ZucaliDaniele Alesini, Andrea Bonetti, Claudia Mucciarini, Maurizio Nicodemo, Alfredo Berruti, Lucia Fratino, Michele Lodde, Caterina Messina, Alessandra Perin, Daniele Santini, Teodoro Sava, Marcello Tucci, Umberto Basso, Francesca Maines, Luca S. Burgio, Enzo Galligioni

Research output: Contribution to journalArticle

Abstract

Aim: To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer. Patients & methods: The multicenter retrospective study was based on a review of the pre-and post-DOC clinical history, DOC treatment and outcomes. Results: We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3-4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival. Conclusion: The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.

Original languageEnglish
Pages (from-to)493-502
Number of pages10
JournalFuture Oncology
Volume12
Issue number4
DOIs
Publication statusPublished - Feb 1 2016

Keywords

  • castration-resistant prostate cancer
  • docetaxel
  • elderly
  • geriatric assessment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Veccia, A., Caffo, O., De Giorgi, U., Di Lorenzo, G., Ortega, C., Scognamiglio, F., Aieta, M., Facchini, G., Mansueto, G., Mattioli, R., Procopio, G., Zagonel, V., D'Angelo, A., Spizzo, G., Bortolus, R., Donini, M., Lo Re, G., Massari, F., Vicario, G., ... Galligioni, E. (2016). Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. Future Oncology, 12(4), 493-502. https://doi.org/10.2217/fon.15.302